Sarah Ackley
@sfackley.bsky.social
Assistant Professor of Epidemiology at Brown University. Dementia Pharmacoepidemiology. Dynamical Modeling. Statistics. Metascience & Knowledge Representation. Cat Mom. She/her.
Reposted by Sarah Ackley
For those of you attending #GSA2025 in Boston, consider this panel of #NIH awardees, Drs. Alden Gross, @mariaglymour.bsky.social , @sfackley.bsky.social , and @bryandjames.bsky.social. Please remember to tag #geronsky and @geronsociety.bsky.social in your posts.
November 6, 2025 at 2:23 PM
For those of you attending #GSA2025 in Boston, consider this panel of #NIH awardees, Drs. Alden Gross, @mariaglymour.bsky.social , @sfackley.bsky.social , and @bryandjames.bsky.social. Please remember to tag #geronsky and @geronsociety.bsky.social in your posts.
Reposted by Sarah Ackley
🔔 #TRCI Special Issue 🔔
Marking the 10th anniversary of AD Drug Development Pipeline articles led by Dr. Jeffrey Cummings!
Submit your research highlighting advances in ADRD clinical trials and drug development!
⏰Oct. 31, 2026
alz-journals.onlinelibrary.wiley.com/hub/journal/...
Marking the 10th anniversary of AD Drug Development Pipeline articles led by Dr. Jeffrey Cummings!
Submit your research highlighting advances in ADRD clinical trials and drug development!
⏰Oct. 31, 2026
alz-journals.onlinelibrary.wiley.com/hub/journal/...
Alzheimer's & Dementia: Translational Research & Clinical Interventions
<em>Alzheimer's & Dementia: Translational Research & Clinical Interventions</em> journal bridges drug discovery research and clinical studies for dementia & Alzheimer's.
alz-journals.onlinelibrary.wiley.com
November 3, 2025 at 9:49 PM
🔔 #TRCI Special Issue 🔔
Marking the 10th anniversary of AD Drug Development Pipeline articles led by Dr. Jeffrey Cummings!
Submit your research highlighting advances in ADRD clinical trials and drug development!
⏰Oct. 31, 2026
alz-journals.onlinelibrary.wiley.com/hub/journal/...
Marking the 10th anniversary of AD Drug Development Pipeline articles led by Dr. Jeffrey Cummings!
Submit your research highlighting advances in ADRD clinical trials and drug development!
⏰Oct. 31, 2026
alz-journals.onlinelibrary.wiley.com/hub/journal/...
Reposted by Sarah Ackley
Such a cool paper. #EpiSky @amjepi.bsky.social #DataScience #Reproducibility Led by @sfackley.bsky.social at
@brown-epi.bsky.social
Research on reproducible research funded by NIH/NIA - thank you!
@brown-epi.bsky.social
Research on reproducible research funded by NIH/NIA - thank you!
🔎 Meta-analysis and triangulation depend on credible science.
📈 TIME-AD’s latest paper, led by Dr. Sarah Ackley, examines 20,000+ abstracts using an LLM to determine whether P value trends reflect changes in p-hacking, publication bias, or statistical power.
Read it: tinyurl.com/3f3nuxma
📈 TIME-AD’s latest paper, led by Dr. Sarah Ackley, examines 20,000+ abstracts using an LLM to determine whether P value trends reflect changes in p-hacking, publication bias, or statistical power.
Read it: tinyurl.com/3f3nuxma
September 14, 2025 at 4:19 PM
Such a cool paper. #EpiSky @amjepi.bsky.social #DataScience #Reproducibility Led by @sfackley.bsky.social at
@brown-epi.bsky.social
Research on reproducible research funded by NIH/NIA - thank you!
@brown-epi.bsky.social
Research on reproducible research funded by NIH/NIA - thank you!
Check out our recently published paper at AJE!
academic.oup.com/aje/advance-...
We analyzed 21,332 abstracts (2000-2024) from four major epidemiology journals, extracting 25,288 P values using ChatGPT’s 4o model with few-shot in-context prompting.
#episky #reproducibility #metasci #metascience
academic.oup.com/aje/advance-...
We analyzed 21,332 abstracts (2000-2024) from four major epidemiology journals, extracting 25,288 P values using ChatGPT’s 4o model with few-shot in-context prompting.
#episky #reproducibility #metasci #metascience
Validate User
academic.oup.com
August 28, 2025 at 12:04 AM
Check out our recently published paper at AJE!
academic.oup.com/aje/advance-...
We analyzed 21,332 abstracts (2000-2024) from four major epidemiology journals, extracting 25,288 P values using ChatGPT’s 4o model with few-shot in-context prompting.
#episky #reproducibility #metasci #metascience
academic.oup.com/aje/advance-...
We analyzed 21,332 abstracts (2000-2024) from four major epidemiology journals, extracting 25,288 P values using ChatGPT’s 4o model with few-shot in-context prompting.
#episky #reproducibility #metasci #metascience
Reposted by Sarah Ackley
#TIME-AD is heading to #AAIC25!
📊 We’ll be sharing results from our latest preprint examining whether reductions in brain amyloid—a key Alzheimer’s biomarker—can meaningfully predict changes in cognition and functioning.
🔗 Read the preprint: tinyurl.com/5n8psura
📊 We’ll be sharing results from our latest preprint examining whether reductions in brain amyloid—a key Alzheimer’s biomarker—can meaningfully predict changes in cognition and functioning.
🔗 Read the preprint: tinyurl.com/5n8psura
July 25, 2025 at 6:42 PM
#TIME-AD is heading to #AAIC25!
📊 We’ll be sharing results from our latest preprint examining whether reductions in brain amyloid—a key Alzheimer’s biomarker—can meaningfully predict changes in cognition and functioning.
🔗 Read the preprint: tinyurl.com/5n8psura
📊 We’ll be sharing results from our latest preprint examining whether reductions in brain amyloid—a key Alzheimer’s biomarker—can meaningfully predict changes in cognition and functioning.
🔗 Read the preprint: tinyurl.com/5n8psura
Looking forward to presenting this renanalysis of the A4 study, as well as a simulation study evaluating SILA's ability to detect ceilings in amyloid accumulation at #AAIC25. #ENDALZ
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
Evaluation of Amyloid Removal as a Surrogate for Cognitive Decline: Pilot Analysis in Individual-Level Data from the A4 Study of Solanezumab
Background Amyloid removal has been used as a surrogate outcome in Alzheimer’s disease trials, allowing accelerated approval of aducanumab and lecanemab. The A4 (Alzheimer’s Clinical Trial Consortium ...
www.medrxiv.org
July 25, 2025 at 6:02 PM
Looking forward to presenting this renanalysis of the A4 study, as well as a simulation study evaluating SILA's ability to detect ceilings in amyloid accumulation at #AAIC25. #ENDALZ
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
Reposted by Sarah Ackley
🧠 TIME-AD is now on Bluesky!
#TIME-AD brings together results from different study designs and populations to find what really works to prevent and delay dementia.
Follow along as we share what we’re learning and check out our website to learn more: www.time-ad.org
#EndALZ #EpiSky #NeuroSky
#TIME-AD brings together results from different study designs and populations to find what really works to prevent and delay dementia.
Follow along as we share what we’re learning and check out our website to learn more: www.time-ad.org
#EndALZ #EpiSky #NeuroSky
July 23, 2025 at 8:48 PM
🧠 TIME-AD is now on Bluesky!
#TIME-AD brings together results from different study designs and populations to find what really works to prevent and delay dementia.
Follow along as we share what we’re learning and check out our website to learn more: www.time-ad.org
#EndALZ #EpiSky #NeuroSky
#TIME-AD brings together results from different study designs and populations to find what really works to prevent and delay dementia.
Follow along as we share what we’re learning and check out our website to learn more: www.time-ad.org
#EndALZ #EpiSky #NeuroSky
New preprint up!
Evaluation of Amyloid Removal as a Surrogate for Cognitive Decline: Pilot Analysis in Individual-Level Data from the A4 Study of Solanezumab
www.medrxiv.org/content/10.1...
Evaluation of Amyloid Removal as a Surrogate for Cognitive Decline: Pilot Analysis in Individual-Level Data from the A4 Study of Solanezumab
www.medrxiv.org/content/10.1...
www.medrxiv.org
July 22, 2025 at 9:04 PM
New preprint up!
Evaluation of Amyloid Removal as a Surrogate for Cognitive Decline: Pilot Analysis in Individual-Level Data from the A4 Study of Solanezumab
www.medrxiv.org/content/10.1...
Evaluation of Amyloid Removal as a Surrogate for Cognitive Decline: Pilot Analysis in Individual-Level Data from the A4 Study of Solanezumab
www.medrxiv.org/content/10.1...
Reposted by Sarah Ackley
Excellent talk at #MELODEM2025 by @sfackley.bsky.social evaluating amyloid as a surrogate marker with individual level A4 trial data
One big take away — 5 years was not enough time to see cognitive decline in the placebo group == a major challenge
One big take away — 5 years was not enough time to see cognitive decline in the placebo group == a major challenge
June 25, 2025 at 4:28 PM
Excellent talk at #MELODEM2025 by @sfackley.bsky.social evaluating amyloid as a surrogate marker with individual level A4 trial data
One big take away — 5 years was not enough time to see cognitive decline in the placebo group == a major challenge
One big take away — 5 years was not enough time to see cognitive decline in the placebo group == a major challenge
Reposted by Sarah Ackley
Now at #MELODEM2025 Is reducing/removing amyloid from the brain a reasonable surrogate for slowing/stopping cognitive decline in dementia? @sfackley.bsky.social uses data from the A4 RCT (of solanezumab) to answer this q, ...
@melodem.bsky.social
@melodem.bsky.social
June 25, 2025 at 2:58 PM
Now at #MELODEM2025 Is reducing/removing amyloid from the brain a reasonable surrogate for slowing/stopping cognitive decline in dementia? @sfackley.bsky.social uses data from the A4 RCT (of solanezumab) to answer this q, ...
@melodem.bsky.social
@melodem.bsky.social
I was invited to comment for AlzForum on GLP-1s and dementia.
GLP-1s show promise, but RCTs like GRADE have not demonstrated clear cognitive benefits. Observational studies may be confounded by socioeconomic factors and prescribing patterns.
Read the full comment: www.alzforum.org/papers/gluco...
GLP-1s show promise, but RCTs like GRADE have not demonstrated clear cognitive benefits. Observational studies may be confounded by socioeconomic factors and prescribing patterns.
Read the full comment: www.alzforum.org/papers/gluco...
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial. | ALZFORUM
www.alzforum.org
May 27, 2025 at 9:04 PM
I was invited to comment for AlzForum on GLP-1s and dementia.
GLP-1s show promise, but RCTs like GRADE have not demonstrated clear cognitive benefits. Observational studies may be confounded by socioeconomic factors and prescribing patterns.
Read the full comment: www.alzforum.org/papers/gluco...
GLP-1s show promise, but RCTs like GRADE have not demonstrated clear cognitive benefits. Observational studies may be confounded by socioeconomic factors and prescribing patterns.
Read the full comment: www.alzforum.org/papers/gluco...
In addition to today's NIH-grant-related anxiety, a cat vomited a fur ball in my shoe.
April 24, 2025 at 2:35 AM
In addition to today's NIH-grant-related anxiety, a cat vomited a fur ball in my shoe.
I wrote 1/3 of a page of my grant!
April 14, 2025 at 5:56 PM
I wrote 1/3 of a page of my grant!
So many more people than I realized!
This is what democracy looks like in Providence, RI #handsoff @indivisibleri.bsky.social @indivisible.org @alexagagosz.bsky.social @fitzprov.bsky.social @tednesi.bsky.social @globeri.bsky.social @steveahlquist.bsky.social @nancyklavin.bsky.social
April 7, 2025 at 2:35 AM
So many more people than I realized!
Note on my previous calculation--arguably 1/1000 is too high.
That figure is pretty old by this point and suffers from MAUP, these areas are more akin to LMICs than the typical US counties.
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Estimating national-level measles case–fatality ratios in low-income and middle-income countries: an updated systematic review and modelling study
Although CFRs have declined between 1990 and 2019, there are still large heterogeneities
across locations and ages. One limitation of this systematic review is that we were
unable to assess measles CF...
www.thelancet.com
April 6, 2025 at 6:38 PM
Note on my previous calculation--arguably 1/1000 is too high.
1/ The number of deaths (3) in this measles outbreak seems high given its size (480 TX + 50 OK + 10 NM = 544).
Typically, ~1/1000 die from measles based on past data (pre- and post-elimination).
Is it possible cases are underreported?
#episky
Typically, ~1/1000 die from measles based on past data (pre- and post-elimination).
Is it possible cases are underreported?
#episky
April 6, 2025 at 4:40 PM
1/ The number of deaths (3) in this measles outbreak seems high given its size (480 TX + 50 OK + 10 NM = 544).
Typically, ~1/1000 die from measles based on past data (pre- and post-elimination).
Is it possible cases are underreported?
#episky
Typically, ~1/1000 die from measles based on past data (pre- and post-elimination).
Is it possible cases are underreported?
#episky
Some math/physics history I happened across yesterday—
David Hilbert lived to see the Nazis purge many prominent faculty members at the University of Göttingen in 1933, including Hermann Weyl, Emmy Noether, and Edmund Landau. (Wikipedia)
David Hilbert lived to see the Nazis purge many prominent faculty members at the University of Göttingen in 1933, including Hermann Weyl, Emmy Noether, and Edmund Landau. (Wikipedia)
April 5, 2025 at 2:14 AM
Some math/physics history I happened across yesterday—
David Hilbert lived to see the Nazis purge many prominent faculty members at the University of Göttingen in 1933, including Hermann Weyl, Emmy Noether, and Edmund Landau. (Wikipedia)
David Hilbert lived to see the Nazis purge many prominent faculty members at the University of Göttingen in 1933, including Hermann Weyl, Emmy Noether, and Edmund Landau. (Wikipedia)
Reposted by Sarah Ackley
Breaking News: The Trump administration intends to block $510 million in federal contracts and grants for Brown University.
Trump Administration Set to Pause $510 Million for Brown University
The administration has now targeted five schools’ federal funding as part of a pledge to combat what it considers to be antisemitism on university campuses.
www.nytimes.com
April 3, 2025 at 10:30 PM
Breaking News: The Trump administration intends to block $510 million in federal contracts and grants for Brown University.
Of all the important questions and issues raised here, the least pressing (but still curious) is... why is the thumbnail a photo of MIT?
www.msn.com/en-us/news/p...
www.msn.com/en-us/news/p...
MSN
www.msn.com
April 2, 2025 at 2:21 PM
Of all the important questions and issues raised here, the least pressing (but still curious) is... why is the thumbnail a photo of MIT?
www.msn.com/en-us/news/p...
www.msn.com/en-us/news/p...
Hmmm… This must be why my work backpack is always covered in cat fur
March 26, 2025 at 4:55 AM
Hmmm… This must be why my work backpack is always covered in cat fur
Science, Anti-Science, Pseudoscience, Truth--very timely & relevant themes in this excerpt on Feyerabend. Fascinating read.
Some general + epi-specific thoughts:
🔗 www.thephilosopher1923.org/post/pseudos...
Some general + epi-specific thoughts:
🔗 www.thephilosopher1923.org/post/pseudos...
"Pseudoscience after Feyerabend": Chiara Ambrosio and Ian James Kidd (Keywords: Epistemology; Objectivity; Science; Authority; Astrology)
"The criteria we use to discuss science and pseudoscience are incredibly context dependent."
www.thephilosopher1923.org
March 12, 2025 at 4:56 PM
Science, Anti-Science, Pseudoscience, Truth--very timely & relevant themes in this excerpt on Feyerabend. Fascinating read.
Some general + epi-specific thoughts:
🔗 www.thephilosopher1923.org/post/pseudos...
Some general + epi-specific thoughts:
🔗 www.thephilosopher1923.org/post/pseudos...
Stand Up for Science in Providence!
March 7, 2025 at 7:57 PM
Stand Up for Science in Providence!
Struggling to compare treatment effects across different cognitive measures?
Check out our new paper.
alz-journals.onlinelibrary.wiley.com/doi/full/10....
Check out our new paper.
alz-journals.onlinelibrary.wiley.com/doi/full/10....
Methods to crosswalk between cognitive test scores using data from the Alzheimer's Disease Neuroimaging Cohort
INTRODUCTION Studies use multiple different instruments to measure dementia-related outcomes, making head-to-head comparisons of interventions difficult. METHODS To address this gap, we developed ...
alz-journals.onlinelibrary.wiley.com
February 26, 2025 at 4:54 AM
Struggling to compare treatment effects across different cognitive measures?
Check out our new paper.
alz-journals.onlinelibrary.wiley.com/doi/full/10....
Check out our new paper.
alz-journals.onlinelibrary.wiley.com/doi/full/10....
A couple thoughts on Piller's piece that didn't fit in my letter.
First:
Anti-amyloid treatments appear to cause brain shrinkage-- this is definitely a concern. But we don't actually know if it's bad and there's reason to think it might not be. We need individual-level data to know for sure!
First:
Anti-amyloid treatments appear to cause brain shrinkage-- this is definitely a concern. But we don't actually know if it's bad and there's reason to think it might not be. We need individual-level data to know for sure!
Check out my letter on amyloid-targeting drugs in STAT!
www.statnews.com/2025/02/22/l...
A thread
#episky
www.statnews.com/2025/02/22/l...
A thread
#episky
Is there an amyloid mafia? STAT readers weigh in
“Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to the editor this week.
www.statnews.com
February 22, 2025 at 5:15 PM
A couple thoughts on Piller's piece that didn't fit in my letter.
First:
Anti-amyloid treatments appear to cause brain shrinkage-- this is definitely a concern. But we don't actually know if it's bad and there's reason to think it might not be. We need individual-level data to know for sure!
First:
Anti-amyloid treatments appear to cause brain shrinkage-- this is definitely a concern. But we don't actually know if it's bad and there's reason to think it might not be. We need individual-level data to know for sure!